关于上海辰光医疗科技股份有限公司 控股股东以及实际控制人为公司提供担保暨关联交易 的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海辰光医疗科技股份有限公司（以下简称"辰光医疗"或"公司"）向不特定 合格投资者公开发行股票并在北交所上市持续督导的保荐机构，根据《证券发 行上市保荐业务管理办法》《北京证券交易所股票上市规则（试行）》《北京证券 交易所证券发行上市保荐业务管理细则》等相关法律、法规和规范性文件的规 定，对公司控股股东及实际控制人王杰先生为公司提供担保暨关联交易事项进 行了核查，核查情况与意见如下： 国泰海通证券股份有限公司 一、控股股东以及实际控制人为公司提供担保暨关联交易概述 1、公司拟向厦门国际银行股份有限公司上海分行申请并使用人民币 2,000 万元的综合授信，期限为 12 个月，用于补充流动资金。控股股东及实际控制人 王杰先生提供连带责任保证担保。在实际贷款业务发生时，根据银行要求实施。 2、公司拟向宁波银行股份有限公司上海分行申请并使用人民币 1,000 万元 的综合授信，期限为 12 个月，用于补充流动资金。控股股东及实际控制人王杰 先生提供连带责任保 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-028 上海辰光医疗科技股份有限公司 董事会审计委员会 2024 年年度履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 上海辰光医疗科技股份有限公司（以下简称"公司"）第五届董事会审计委 员会（以下简称"审计委员会"）根据《公司法》《证券法》《上市公司独立董 事管理办法》《北京证券交易所股票上市规则（试行）》及《公司章程》《审计 委员会议事规则》等相关法律法规及公司制度的规定和要求，忠实勤勉地履行了 工作职责。现将本年度履职情况汇报如下： 一、基本情况 截至 2024 年 12 月 31 日，公司第五届董事会审计委员会由三名董事组成， 分别为李振翮先生、侯晓远先生和郭宁女士，其中，侯晓远为公司董事，李振翮、 郭宁为公司独立董事，审计委员会主任委员由专业会计人士李振翮先生担任。 二、会议召开情况 2024 年，审计委员会按照有关法律法规的要求，充分发挥审查、监督作用， 勤勉尽责地开展工作，为完善公司治理、提高内部审计和外部审计工 ...

Group 1 - The core business of the company is the research, production, and sales of superconducting MRI systems and special magnets in high-tech fields [1] - The company has received several recognitions, including being named a "Technology Little Giant" enterprise in Shanghai and a national-level "Specialized and Innovative" small giant enterprise [1] - The latest financial results show a revenue of 86.11 million yuan for the third quarter of 2024, representing a year-on-year decrease of 13.44%, with a net loss of approximately 15.88 million yuan, a year-on-year decline of 129.77% [1] Group 2 - The company's current price-to-earnings (P/E) ratio is -25.68, with a price-to-book (P/B) ratio of 5.45 and a total market capitalization of 1.489 billion yuan [2] - The industry average P/E ratio is 48.08, while the industry median is 30.21, indicating that the company is significantly below industry benchmarks [2] - The company has experienced a net outflow of 15.09 million yuan in principal funds on April 22, with a total outflow of 40.22 million yuan over the past five days [1]

Group 1 - The core business of the company is the research, production, and sales of superconducting MRI systems and special magnets in high-tech fields [1] - The company has received several recognitions, including "Technology Little Giant Enterprise" and "Specialized and Innovative Small Giant Enterprise" at both municipal and national levels [1] - The latest financial results show a revenue of 86.11 million yuan for the third quarter of 2024, representing a year-on-year decrease of 13.44%, with a net loss of approximately 15.88 million yuan, a year-on-year decline of 129.77% [1] Group 2 - The company's current price-to-earnings (PE) ratio is -26.85, with a price-to-book (PB) ratio of 5.70 and a total market capitalization of 1.557 billion yuan [2] - The industry average PE ratio is 45.94, while the industry median is 29.64, indicating that the company is significantly below industry averages [2] - The company has experienced a net outflow of 16.31 million yuan in principal funds on April 16, with a total outflow of 17.75 million yuan over the past five days [1]

4月14日，辰光医疗今日收盘20.21元，上涨3.59%，最新市净率6.35，总市值17.35亿元。 资金流向方面，4月14日，辰光医疗主力资金净流入838.77万元，近5日总体呈流入状态，5日共流入 4001.37万元。 最新一期业绩显示，2024年三季报，公司实现营业收入8610.63万元，同比-13.44%；净利 润-15875336.84元，同比-129.77%，销售毛利率41.27%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13辰光医疗-29.91-29.916.3517.35亿行业平均 45.7149.434.75102.82亿行业中值29.9929.792.3746.97亿1硕世生物-1863.40-1863.401.1738.50亿2诺唯 赞-532.18-532.182.4496.29亿3博晖创新-364.57-224.464.0255.96亿4康泰医学-267.7531.412.7452.07亿5华 大基因-201.24220.132.08204.50亿6奥精医疗-109.83-109.831.4019.90亿7睿昂基因-80.13-80.131.2511.59亿 8热景生 ...

Group 1 - The core business of the company is the research, production, and sales of superconducting MRI systems and specialized magnets in the high-tech field [1] - As of the latest quarterly report for Q3 2024, the company reported a revenue of 86.11 million yuan, a year-on-year decrease of 13.44%, and a net loss of approximately 15.88 million yuan, a year-on-year decline of 129.77% [1] - The company has a current market capitalization of 1.744 billion yuan and a price-to-book ratio of 6.39 [1] Group 2 - The company is recognized as a high-tech enterprise with a focus on independent research and development, having received several accolades including "Technology Small Giant Enterprise" and "National Specialized and New Small Giant Enterprise" [1] - The company has one institutional holder, which is a fund holding a total of 47,300 shares valued at 0.01 million yuan [1] - The average price-to-earnings (PE) ratio in the industry is significantly higher at 45.15 compared to the company's PE ratio of -30.08 [2]

Company Overview - Chuangguang Medical closed at 20.04 yuan on April 8, with a rise of 12.84%, and a latest price-to-book ratio of 6.30, marking a new low in 15 days, with a total market capitalization of 1.72 billion yuan [1] - The company specializes in the research, production, and sales of superconducting MRI systems and special magnets in high-tech fields, with main products including MRI systems, superconducting magnets, RF detectors, and related hardware and accessories [1] - Chuangguang Medical is recognized as a high-tech enterprise focusing on independent research and development, having received several accolades including "Technology Small Giant Enterprise" and "Specialized and New Small Giant Enterprise" at both municipal and national levels [1] Financial Performance - For the latest reporting period, the company reported operating revenue of 86.11 million yuan, a year-on-year decrease of 13.44%, and a net loss of approximately 15.88 million yuan, representing a year-on-year decline of 129.77%, with a gross profit margin of 41.27% [1] Market Position - The company has a TTM PE ratio of -29.66 and a static PE ratio of -29.66, with a market capitalization of 1.72 billion yuan, which is significantly lower than the industry average PE of 44.58 and the industry median PE of 28.55 [2] - The company’s market valuation is also lower than several peers in the industry, indicating potential undervaluation compared to competitors [2]

一、辞职董监高的基本情况 （一）基本情况 证券代码：430300 证券简称：辰光医疗 公告编号：2025-016 上海辰光医疗科技股份有限公司 职工代表监事辞职公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 三、备查文件 本公司监事会于 2025 年 3 月 28 日收到职工代表监事张梅卿女士递交的辞职报告， 自 2025 年 3 月 28 日起辞职生效。上述辞职人员持有公司股份 0 股，占公司股本的 0%。 不是失信联合惩戒对象，辞职后不再担任公司其它职务。 （二）辞职原因 张梅卿女士因个人原因辞去职工代表监事职务。 二、上述人员的辞职对公司产生的影响 （一）本次辞职未导致公司董事会成员人数低于法定最低人数，未导致公司监事会成员 人数低于法定最低人数，未导致职工代表监事人数少于监事会成员的三分之一，未导 致董事会中兼任高级管理人员的董事和由职工代表担任的董事人数超过公司董事总数 的二分之一，未导致董事会或者其专门委员会中独立董事所占的比例不符合相关规则 或者公司章程的规定，未导致独立董事中欠缺会计 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-017 上海辰光医疗科技股份有限公司 2025 年第一次职工代表大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 1 日 2.会议召开地点：上海辰光医疗科技股份有限公司会议室 3.会议召开方式：现场会议 （二）会议出席情况 出席本次职工代表大会的职工代表共计 118 人。 二、议案审议情况 （一）审议通过《关于选举公司第五届监事会职工代表监事的议案》 1.议案内容： 公司第五届监事会职工代表监事张梅卿女士因个人原因申请辞去公司职工 代表监事职务。为保证监事会正常运行，公司职工代表大会选举李斯女士为公司 第五届监事会职工代表监事，任职期限至第五届监事会届满之日止。 经资格审核，李斯女士不属于失信联合惩戒对象，不存在《公司法》《证券 法》《北京证券交易所股票上市规则（试行）》和《公司章程》所规定的不得担任 上市公司监事的情形，具备担任上市公司监事任职 ...

上海辰光医疗科技股份有限公司监事任命公告 证券代码：430300 证券简称：辰光医疗 公告编号：2025-018 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、任免基本情况 （一）任免的基本情况 上海辰光医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 1 日召开 2025 年第一次职工代表大会，审议通过《关于选举公司第五届监事会职工代表监事的议案》。 选举李斯女士为公司职工代表监事，任职期限至第五届监事会届满为止，自 2025 年 4 月 1 日起生效。上述选举人员持有公司股份 0 股，占公司股本的 0%，不是失信联 合惩戒对象。 （二）任命原因 公司第五届监事会职工代表监事张梅卿女士因个人原因申请辞去公司职工代表监 事职务，为保证监事会正常运行，公司职工代表大会选举李斯女士为公司第五届监事会 职工代表监事。 公司新任董事、监事、高级管理人员候选人的任职资格符合法律法规、部门规章、 业务规则和公司章程等规定。本次任命未导致董事会中兼任高级管理人员的董事和由职 工代表担任的董事人数超 ...